A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Multiple Myeloma and Malignant Plasma Cell Neoplasms
Interventions
DRUG

18F-FDG

Prior to the examination, patients will be required to fast for at least 6 hours. 18F-FDG (0.05-0.1 mCi/kg) will be intravenously injected, and one hour after the injection, head and torso imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the upper third of the thigh. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.

DRUG

68Ga-BC1

The prepared and quality-controlled 68Ga-BC1 (0.05-0.1 mCi/kg) will be intravenously injected into the patient. Two hours after the injection, whole-body imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the mid-thigh. If any indeterminate lesions are found during the routine imaging, delayed imaging will be performed for further differentiation. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.

Trial Locations (2)

100000

ENROLLING_BY_INVITATION

Peking University First Hospital, Beijing

010000

RECRUITING

Department of Nuclear Medicine, Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT06717113 - A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma | Biotech Hunter | Biotech Hunter